1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Aptar Pharma Enters Agreement with Pulmotree to Develop and Promote Kolibri NPLI Platform

12 Sep 2024
Admin
News Article

Aptar Pharma Enters Agreement with Pulmotree to Develop and Promote Kolibri NPLI Platform

Overview

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announced that it has entered into an exclusive collaboration agreement with Pulmotree, a Munich-based life science company, to lead the development and promotion of their Kolibri Non-Propellant Liquid Inhaler (NPLI) platform. As part of the agreement, Aptar Pharma will provide Pulmotree with their full support to accelerate growth, be the main point of contact for customers, and have the ability to complement the Kolibri NPLI Platform Technology with Aptar’s suite of comprehensive services.

Non-Propellant Liquid Inhalers

Non-Propellant Liquid Inhalers encompass nebulizers and soft-mist inhalers, and are being developed as an alternative to propellant-based systems.
Pulmotree’s Kolibri utilizes a robust breath-triggered Vibrating Mesh aerosolization engine with unique breath-guidance capabilities to enhance targeted lung deposition.
The Kolibri technology is award-winning and incorporates advanced connectivity features.

Statement from Aptar Pharma

Howard Burnett, vice president, global pulmonary category, Aptar Pharma, stated, “Pulmotree has solid experience in the NPLI field and Aptar Pharma is delighted to be able to offer the Kolibri technology in collaboration with such a knowledgeable partner, to be able to provide full support to all drug developers, from formulation development to patient onboarding.”

Statement from Pulmotree

Ulf Krüger, CEO of Pulmotree, stated, “With this alliance, pharmaceutical partners can access an unprecedented portfolio of services from Aptar Pharma as a single source, in the development of combination products to accelerate product development. For Pulmotree, this important step enables us to continue to grow sustainably and expand our portfolio.”

Impact of Collaboration

This collaboration further strengthens Aptar Pharma’s leadership in respiratory by offering a broader range of drug delivery formats, solutions and services.
By leveraging offerings within Aptar Pharma companies such as Nanopharm’s formulation development and analytical expertise, Noble’s Human Factors support and patient onboarding, and Aptar Digital Health’s services, Aptar Pharma can customize drug formulation development, optimize device design, and differentiate with improved patient outcomes to provide their customers with a value-added finished product.

Vice president Aptar Pharma Continuous

Added Howard Burnett, “With this partnership, Aptar and Pulmotree can provide a unique offer to the market to tune and tailor both formulation and delivery system seamlessly, and support drug development, to enable intuitive and efficient delivery in the hands of patients.”

About Pulmotree

Pulmotree is a Munich-based life science company specializing in the development of drug delivery systems with targeted deposition of small and large molecule formulations into specific areas of the lung.

About Aptar Pharma

Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions.